Johnson & Johnson reported robust second-quarter results with overall sales reaching $23.7 billion, a 4.6% increase year-over-year, driven by strong medical device performance and innovative medicines. Its pharmaceutical division crossed $15 billion in sales for the first time, despite a 43% revenue decline in Stelara due to biosimilar competition. Growth was fueled by oncology drugs, including Darzalex and Carvykti, and immunology products like Tremfya, which showed significant sales increases. J&J expects to be the leading oncology company by 2030 and raised its income guidance, reflecting growth in multiple therapeutic areas.